Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd > Financing - 54 Cents

<< Previous

Bullboard Posts

Next >>

Comment by duchebaggieon Jan 31, 2013 11:04am

148 Views

Post# 20917359

RE: Financing - 54 Cents

Even though it seems very optimistic, I agree with you LakeErie that they probably have an idea of the 43-101 that's coming up. Otherwise, I think they would have never done the offering @ 0.54 IMHO. However, is it really part of a communication strategy leading up to PDAC? I'm not convinced.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments